Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastric Ulcer Clear all
Completed Phase 3 Interventional Results available

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

NCT00441727
View directory record Official record
Conditions
Gastric Ulcer, Duodenal Ulcer
Interventions
Esomeprazole 40 mg, Esomeprazole 20 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
55
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 8, 2026, 11:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

NCT00942175
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 8, 2026, 11:51 AM EDT
Completed No phase listed Observational

Pharmacist-Driven Stress Ulcer Prophylaxis Minimization in the Intensive Care Unit

NCT06225167
View directory record Official record
Conditions
Stress Ulcer
Interventions
To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.
Behavioral
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 8, 2026, 11:51 AM EDT
Completed No phase listed Observational

Endoscopic Therapy for Bleeding Marginal Ulcers After Gastric Bypass

NCT01040416
View directory record Official record
Conditions
Bleeding Marginal Ulcer
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2009 · Synced Sep 8, 2026, 11:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Interaction Between Aspirin and Nexium

NCT01199328
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Aspirin, Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Sep 8, 2026, 11:51 AM EDT
Completed No phase listed Observational

Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome

NCT00001254
View directory record Official record
Conditions
Zollinger Ellison Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 8, 2026, 11:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

NCT00284908
View directory record Official record
Conditions
Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
Interventions
S-Tenatoprazole-Na (STU-Na)
Drug
Lead sponsor
STEBA France
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2008 · Synced Sep 8, 2026, 11:51 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

NCT00594854
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PN400 (VIMOVO), Diclofenac/Misoprostol
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Sep 8, 2026, 11:51 AM EDT
Terminated Not applicable Interventional

Quantifying Effects of Treatment of Pediatric Dysphonia

NCT00237679
View directory record Official record
Conditions
Voice Disorders, Gastroesophageal Reflux
Interventions
Neuromuscular Electrical Stimulation, Unstimulated
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
6 Years to 11 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 8, 2026, 11:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers

NCT00778193
View directory record Official record
Conditions
Gastroduodenal Ulcer
Interventions
Naproxen, Aspirin, Celecoxib, Clopidogrel, Placebo
Drug
Lead sponsor
Research Associates of New York, LLP
Other
Eligibility
18 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2008 · Synced Sep 8, 2026, 11:51 AM EDT
Completed No phase listed Observational

Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects

NCT03060746
View directory record Official record
Conditions
Helicobacter Pylori Infection, Gastric Ulcer, Nausea, Abdominal Pain, Weight Loss, Stomach Ulcer, Loss of Appetite, Bloating
Interventions
Newly Diagnosed
Other
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
22 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Mesa, Arizona • Mission Hills, California • Oxnard, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 8, 2026, 11:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Sep 8, 2026, 11:51 AM EDT
Completed No phase listed Observational

Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects

NCT03060733
View directory record Official record
Conditions
Helicobacter Pylori Infection, Gastric Ulcer, Nausea, Abdominal Pain, Weight Loss, Stomach Ulcer, Loss of Appetite, Bloating
Interventions
Post-Therapy
Other
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
22 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Mission Hills, California • Great Neck, New York • Mentor, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 8, 2026, 11:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

NCT00325715
View directory record Official record
Conditions
Peptic Ulcer
Interventions
AGN 201904, esomeprazole
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Sep 8, 2026, 11:51 AM EDT
Completed Phase 4 Interventional

An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium

NCT00428701
View directory record Official record
Conditions
Gastric Ulcer
Interventions
Esomeprazole Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
5
States / cities
Newark, Delaware • Shreveport, Louisiana • Hershey, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2011 · Synced Sep 8, 2026, 11:51 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

NCT00367211
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole)
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 8, 2026, 11:51 AM EDT
Terminated No phase listed Observational

Systems Biology of Gastrointestinal and Related Diseases

NCT05579444
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 8, 2026, 11:51 AM EDT
Not yet recruiting Not applicable Interventional

Sling-Fiber Preservation POEM vs. Conventional POEM for Reducing Post-POEM GERD

NCT07178821
View directory record Official record
Conditions
Achalasia, Esophageal, GERD (Gastroesophageal Reflux Disease)
Interventions
Conventional POEM, Sling Fiber-Preserving POEM
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 8, 2026, 11:51 AM EDT
Completed Phase 4 Interventional

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

NCT03667703
View directory record Official record
Conditions
Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Minute to 12 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 8, 2026, 11:51 AM EDT
Completed Phase 2Phase 3 Interventional

Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®

NCT01063920
View directory record Official record
Conditions
Osteoarthritis
Interventions
LT-NS001, Naprosyn®
Drug
Lead sponsor
Logical Therapeutics
Industry
Eligibility
45 Years to 80 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
65
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2011 · Synced Sep 8, 2026, 11:51 AM EDT
Completed Phase 1 Interventional

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions
Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 8, 2026, 11:51 AM EDT
Completed No phase listed Observational

Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)

NCT00212225
View directory record Official record
Conditions
Helicobacter Infections, Gastritis, Peptic Ulcer
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 18 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Sep 8, 2026, 11:51 AM EDT
Recruiting Phase 2 Interventional

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT07223424
View directory record Official record
Conditions
Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular Carcinoma, Ulcerative Colitis, Esophageal Cancer, Squamous Cell Carcinoma, Gastric/GEJ, Cervical Cancer, Gastro-Esophageal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
nivolumab, pembrolizumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 8, 2026, 11:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population

NCT00137033
View directory record Official record
Conditions
Peptic Ulcers
Interventions
Celecoxib, Naproxen, ASA
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
605 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
23
States / cities
Anaheim, California • San Diego, California • Farmington, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 8, 2026, 11:51 AM EDT